Kela ends drug reimbursements, HUS warns of unequal access, high-cost care shifts back to patients

• Kela has decided to stop reimbursing certain high-cost medicines previously covered through the national reimbursement system.
• HUS chief physician Markku Mäkijärvi told Yle the move may increase inequality between patients.
• Kela says the decision is consistent with Finnish healthcare law, which places responsibility for these treatments within public healthcare.
• The change can shift costs and administrative pressure from the reimbursement system to hospitals, municipalities and households, depending on how access is arranged.

Finland’s Social Insurance Institution, Kela, has decided to stop reimbursing a set of expensive medicines, a move that immediately changes how some patients pay for treatment. Writing for Yle reports that HUS chief physician Markku Mäkijärvi warned the decision could increase inequality if patients no longer receive the same access to high-cost drugs through the public system.

According to Yle, Kela’s own chief physician said the decision is in line with the Health Care Act, under which medicines used in public healthcare are to be provided by the wellbeing services counties and hospital districts rather than reimbursed through the national insurance system. That legal distinction matters because it changes the payer. A drug that was previously obtained with Kela reimbursement at the pharmacy may now depend on whether a hospital prescribes, procures and administers it through specialist care. For the patient, the formal right to treatment may remain on paper while the route to getting it becomes narrower, slower and more dependent on local clinical decisions.

Yle’s report frames the dispute around expensive medicines used in specialist care, though the article points above all to the distributional effect rather than a single budget line. If reimbursement disappears, patients with savings can often absorb a period of uncertainty, pay privately, or seek alternatives while appeals and referrals move through the system. Patients without that margin cannot. The result is not necessarily an immediate denial written into law; it can be postponed starts, interrupted treatment, extra hospital bureaucracy and a larger gap between those who can navigate the system and those who wait for it to navigate them.

The fiscal logic is also plain enough. Removing Kela reimbursement does not make the underlying need vanish. Costs can reappear inside hospital budgets, in municipal and county healthcare planning, or in household spending if patients are left to bridge the gap themselves. Universal systems often describe coverage as equal at the point of need. The harder question arrives when budgets tighten and a medicine remains available, but only through a more restrictive channel than before.

That is the pressure point in this Finnish case. Kela says the decision follows the law. HUS says patients may become more unequal. Between those two statements sits the patient who used to collect a medicine from a pharmacy and now needs a hospital to say yes.

Källor: Yle Uutiset